Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited to Report Fiscal First Quarter 2019 Financial Results and Host Conference Call
JERSEY, Channel Islands , July 24, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2018 , will be released after market close on Monday, August 6, 2018 .
View HTML
Toggle Summary Quotient Limited Announces Details of Investor Day
JERSEY, Channel Islands , July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ headquarters in New York earlier today. Following the recent announcement of positive field trial data
View HTML
Toggle Summary Quotient Limited Announces Completion of Senior Secured Notes Offering
JERSEY, Channel Islands , July 02, 2018 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million aggregate principal amount of its 12% Senior Secured Notes due 2023 (the “Notes”).
View HTML
Toggle Summary Quotient Limited to Host Investor Day on July 16, 2018
JERSEY, Channel Islands , June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July 16, 2018 from 9:00am – 1:00pm ET , in New York, NY . At the event, Franz Walt , Chief Executive
View HTML
Toggle Summary Quotient Limited Reports Concordance Data from the MosaiQ European Field Trial
Field trial concordance data exceed targeted criteria Planned issuance of $36 million in Senior Secured Notes JERSEY, Channel Islands , June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported concordance data for the initial MosaiQ
View HTML
Toggle Summary Quotient Limited Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Updates on CEO Appointment and MosaiQ™ European Field Trials
MosaiQ European field trial which commenced on May 17, 2018 is ongoing Franz Walt is appointed as Chief Executive Officer Fourth quarter product revenues of $6.1 million , up 29.6% JERSEY, Channel Islands , May 29, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage
View HTML
Toggle Summary Quotient Limited appoints Franz Walt as Chief Executive Officer
JERSEY, Channel Islands , May 29, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt , as its Chief Executive Officer. Mr Walt who retired earlier this year as the President of Siemens Healthineers ,
View HTML
Toggle Summary Quotient Limited Reports Commencement of EU Blood Grouping Field Trial
JERSEY, Channel Islands , May 17, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported that it has completed the verification and validation (V&V) phase for its initial blood grouping MosaiQ™ microarray (IH I) and has commenced its European
View HTML
Toggle Summary Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call
JERSEY, Channel Islands , May 15, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal full year ended March 31, 2018 , will be released before market open on Tuesday, May 29, 2018 .
View HTML
Toggle Summary Quotient Limited Announces FDA Approval of Seven Blood Bank Reagents, Including Two Market Firsts
JERSEY, Channel Islands , April 24, 2018 /PRNewswire/ -- Quotient Limited (" Quotient") (NASDAQ: QTNT), an established, commercial-stage diagnostics company, today announced the recent FDA approval for U.S. commercialization of seven new blood bank reagents including two market firsts.
View HTML